Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma

Masahiro Kami, Tamae Hamaki, Shigesaburo Miyakoshi, Naoko Murashige, Yoshinobu Kanda, Ryuji Tanosaki, Yoichi Takaue, Shuichi Taniguchi, Hisamaru Hirai, Keiya Ozawa, Masaharu Kasai

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The feasibility of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) in 11 patients with adult T-cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced-intensity) were tolerable. Five patients developed acute graft-versus-host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1-year overall and disease-free survival rates were 53 ± 30% and 45 ± 29% respectively. Four patients remain alive and disease-free at a median follow-up of 25 months. The others died of transplantation-related complications. This pilot study suggests that allo-HSCT in ATL should be evaluated further.

Original languageEnglish
Pages (from-to)304-309
Number of pages6
JournalBritish Journal of Haematology
Volume120
Issue number2
DOIs
Publication statusPublished - 2003 Jan
Externally publishedYes

Fingerprint

Adult T Cell Leukemia Lymphoma
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Therapeutics
Disease-Free Survival
Lymphoma
Survival Rate
Transplantation

Keywords

  • Adult T-cell leukaemia/lymphoma
  • Allogeneic haematopoietic stem-cell transplantation
  • Graft-versus-host disease
  • Graft-versus-leukaemia effect
  • Regimen-related toxicity

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. / Kami, Masahiro; Hamaki, Tamae; Miyakoshi, Shigesaburo; Murashige, Naoko; Kanda, Yoshinobu; Tanosaki, Ryuji; Takaue, Yoichi; Taniguchi, Shuichi; Hirai, Hisamaru; Ozawa, Keiya; Kasai, Masaharu.

In: British Journal of Haematology, Vol. 120, No. 2, 01.2003, p. 304-309.

Research output: Contribution to journalArticle

Kami, M, Hamaki, T, Miyakoshi, S, Murashige, N, Kanda, Y, Tanosaki, R, Takaue, Y, Taniguchi, S, Hirai, H, Ozawa, K & Kasai, M 2003, 'Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma', British Journal of Haematology, vol. 120, no. 2, pp. 304-309. https://doi.org/10.1046/j.1365-2141.2003.04054.x
Kami, Masahiro ; Hamaki, Tamae ; Miyakoshi, Shigesaburo ; Murashige, Naoko ; Kanda, Yoshinobu ; Tanosaki, Ryuji ; Takaue, Yoichi ; Taniguchi, Shuichi ; Hirai, Hisamaru ; Ozawa, Keiya ; Kasai, Masaharu. / Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. In: British Journal of Haematology. 2003 ; Vol. 120, No. 2. pp. 304-309.
@article{2393d4123c584e3ab9b5bbd38134301a,
title = "Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma",
abstract = "The feasibility of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) in 11 patients with adult T-cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced-intensity) were tolerable. Five patients developed acute graft-versus-host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1-year overall and disease-free survival rates were 53 ± 30{\%} and 45 ± 29{\%} respectively. Four patients remain alive and disease-free at a median follow-up of 25 months. The others died of transplantation-related complications. This pilot study suggests that allo-HSCT in ATL should be evaluated further.",
keywords = "Adult T-cell leukaemia/lymphoma, Allogeneic haematopoietic stem-cell transplantation, Graft-versus-host disease, Graft-versus-leukaemia effect, Regimen-related toxicity",
author = "Masahiro Kami and Tamae Hamaki and Shigesaburo Miyakoshi and Naoko Murashige and Yoshinobu Kanda and Ryuji Tanosaki and Yoichi Takaue and Shuichi Taniguchi and Hisamaru Hirai and Keiya Ozawa and Masaharu Kasai",
year = "2003",
month = "1",
doi = "10.1046/j.1365-2141.2003.04054.x",
language = "English",
volume = "120",
pages = "304--309",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma

AU - Kami, Masahiro

AU - Hamaki, Tamae

AU - Miyakoshi, Shigesaburo

AU - Murashige, Naoko

AU - Kanda, Yoshinobu

AU - Tanosaki, Ryuji

AU - Takaue, Yoichi

AU - Taniguchi, Shuichi

AU - Hirai, Hisamaru

AU - Ozawa, Keiya

AU - Kasai, Masaharu

PY - 2003/1

Y1 - 2003/1

N2 - The feasibility of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) in 11 patients with adult T-cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced-intensity) were tolerable. Five patients developed acute graft-versus-host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1-year overall and disease-free survival rates were 53 ± 30% and 45 ± 29% respectively. Four patients remain alive and disease-free at a median follow-up of 25 months. The others died of transplantation-related complications. This pilot study suggests that allo-HSCT in ATL should be evaluated further.

AB - The feasibility of allogeneic haematopoietic stem-cell transplantation (allo-HSCT) in 11 patients with adult T-cell leukaemia/lymphoma (ATL) (6 acute, 4 lymphoma, 1 chronic type) was evaluated. The preparative regimens (9 conventional, 2 reduced-intensity) were tolerable. Five patients developed acute graft-versus-host disease (GVHD), and three, extensive chronic GVHD. All 10 patients who survived > 30 d achieved complete remission. Estimated 1-year overall and disease-free survival rates were 53 ± 30% and 45 ± 29% respectively. Four patients remain alive and disease-free at a median follow-up of 25 months. The others died of transplantation-related complications. This pilot study suggests that allo-HSCT in ATL should be evaluated further.

KW - Adult T-cell leukaemia/lymphoma

KW - Allogeneic haematopoietic stem-cell transplantation

KW - Graft-versus-host disease

KW - Graft-versus-leukaemia effect

KW - Regimen-related toxicity

UR - http://www.scopus.com/inward/record.url?scp=0037272683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037272683&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04054.x

DO - 10.1046/j.1365-2141.2003.04054.x

M3 - Article

VL - 120

SP - 304

EP - 309

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -